Management ChangeMay 6, 2026, 08:47 AM
Actuate Therapeutics Appoints Martin Huber, MD, as Independent Director
AI Summary
Actuate Therapeutics, Inc. announced the immediate appointment of Martin Huber, MD, as an Independent Director to its Board. This strategic addition aims to bolster the company's leadership as it progresses its lead investigational drug, elraglusib, through registration studies and towards commercialization for various difficult-to-treat cancers. Dr. Huber brings decades of experience in drug development and oncology, having previously served as CEO of Mersana Therapeutics and held key R&D roles at Xilio Therapeutics and TESARO.
Key Highlights
- Actuate Therapeutics appointed Martin Huber, MD, as an Independent Director, effective immediately.
- Dr. Huber's appointment strengthens the leadership team as Actuate advances elraglusib for cancer treatments.
- Dr. Huber recently served as President and CEO of Mersana Therapeutics until its acquisition in January 2026.
- He held senior R&D leadership roles at Xilio Therapeutics and TESARO, including Chief Medical Officer.
- Dr. Huber contributed to the approval of multiple oncology medicines, including pembrolizumab and niraparib.
- He emphasized Actuate's focus on GSK-3\u03b2 inhibition and recent impressive results in metastatic pancreatic cancer.
Price Impact
More from ACTU